Home   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  • Wnt/Stem Cell
  • Epigenetics
  >  
JAK
  >   Baricitinib phosphate
Baricitinib phosphate Chemical Structure

Baricitinib phosphate

Data Sheet For research use only. Not for human use.
Cat. No. :BCP15527CAS No. :1187595-84-1Purity:98%
 Tel: 0086-13026320035   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 1187595-84-1 Cat. No. BCP15527
Name Baricitinib phosphate
Synonyms INCB-28050;INCB28050;INCB 28050;LY3009104;LY 3009104;LY-3009104;
SMILES
Chemical Name
Formula C16H20N7O6PS M. Wt 469.41
Purity 98% Storage Store at 4-8°C
Description INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. Significant efficacy, as assessed by improvements in clinical, histologic and radiographic signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3 . in vivo: The efficacy following daily oral administration of INCB028050 was assessed at doses of 1, 3, or 10 mg/kg based on its pharmacokinetic profile in this species. Disease severity was assessed periodically, scoring clinical signs of disease. These doses were based on the PK/PD relationship established with the IL-6 WBA, with the goal of inhibiting JAK1/2 signaling by no more than 50% for half of the day. Relative to vehicle-treated animals, increasing doses of INCB028050 inhibited disease scores by 24% (p < 0.05), 57% (p < 0.01), and 81% (p < 0.01), respectively . Baricitinib preferent
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Baricitinib phosphate supplier,Baricitinib phosphate purchase,Baricitinib phosphate manufacturer,Baricitinib phosphate distributor,Baricitinib phosphate cost,Baricitinib phosphate buy,Baricitinib phosphate for sale

0086-13720134139